Latest Earnings Results: Q2 '26
Estimated EPS
-$0.24
Reported EPS
-$0.23
Surprise
+4.17%
Estimated Rev
$0.44M
Reported Rev
$0.24M
Surprise
-45.37%
Insight Molecular Diagnostics Inc. reported Q2 2026 revenue of approximately $239,000 with a gross profit of $157,000, representing a 65.7% gross margin, while the net loss reached $11.3 million for the quarter.
Bullish Takeaway
Insight Molecular Diagnostics Inc. is advancing toward FDA authorization for GraftAssureDx, supported by favorable Medicare reimbursement expansion and strong clinical data validating the performance and market potential of the company's technology.
Bearish Takeaway
Insight Molecular Diagnostics Inc. remains in a pre-revenue stage with significant quarterly cash burn and net losses, while facing substantial regulatory, operational, and capital-related risks ahead of potential product commercialization.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.22 | -- | -- | N/A |
Q2 '26 | -$0.24 | -$0.23 | 4.17% | BEAT |
Q1 '26 | -$0.26 | -$0.12 | 54.12% | BEAT |
Q4 '25 | -$0.24 | -$0.72 | -203.16% | MISSED |
Q3 '25 | -$0.21 | -$0.20 | 4.74% | BEAT |